Related Experiment Videos
Hyperhomocysteinemia in end stage renal disease: is treatment necessary?
Insights
Elevated homocysteine (Hcy) is common in end-stage renal disease (ESRD) and linked to cardiovascular disease (CVD) risk. Further research is needed to confirm if lowering Hcy in ESRD patients reduces CVD incidence.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Biochemistry
Background:
- Hyperhomocysteinemia affects 85% of end-stage renal disease (ESRD) patients.
- Elevated homocysteine (Hcy) is a potential contributor to the high cardiovascular disease (CVD) morbidity and mortality in ESRD.
- Preventative strategies for CVD in ESRD patients are a significant clinical challenge.
Purpose of the Study:
- To highlight the association between hyperhomocysteinemia and CVD risk in ESRD.
- To review current research on treating hyperhomocysteinemia in renal patients.
- To emphasize the need for nephrology nurses to integrate knowledge of Hcy in ESRD into clinical practice.
Main Methods:
- Literature review of studies concerning hyperhomocysteinemia treatment in ESRD patients.
- Analysis of the current understanding of homocysteine (Hcy) pathophysiology in renal disease.
- Discussion of the potential impact of Hcy reduction on CVD incidence.
Main Results:
- Hyperhomocysteinemia is highly prevalent in ESRD patients.
- Evidence supporting the benefit of lowering Hcy levels to decrease CVD incidence in ESRD is currently lacking.
- The role of Hcy in ESRD-related CVD requires further investigation.
Conclusions:
- Nephrology nurses must be informed about hyperhomocysteinemia in ESRD.
- Understanding Hcy pathophysiology and treatment is crucial for clinical practice in nephrology.
- Further research is essential to establish the efficacy of Hcy lowering therapies for CVD prevention in ESRD patients.
Abstract:
Hyperhomocysteinemia occurs in 85% of patients with end stage renal disease (ESRD) and may contribute to their increased risk of cardiovascular disease (CVD). This population experiences excess morbidity and mortality due to CVD, presenting a unique challenge in terms of preventative medicine. The treatment of hyperhomocysteinemia in the renal population has been a topic recently considered in published studies. It is thought, but not yet supported by evidence, that lowering homocysteine (Hcy) levels in ESRD patients will decrease the incidence of CVD. Nephrology nurses need to be aware of the pathophysiology, treatment, and current research regarding hyperhomocysteinemia in patients with ESRD and integrate this knowledge into clinical practice.